Therapeutic indicationsparicalcitol is indicated in adults for the prevention and treatment of secondary hyperparathyroidism in patients with chronic kidney disease stage 5 who are undergoing haemodialysis.paricalcitol is a synthetic, biologically active vitamin d analogue of calcitriol with modifications to the side chain (d2) and the a (19-nor) ring. unlike calcitriol, paricalcitol is a selective vitamin d receptor (vdr) activator.